1.	Efficacy of G-CSF-Priming in Elderly AML Patients Phase: Phase IV Type: Treatment Status: Active Age: Over 60 Sponsor: Other Protocol IDs: AML-elderly 01/99 Trial, NCT00199147
2.	AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years Phase: Phase IV Type: Treatment Status: Active Age: 16 to 60 Sponsor: Other Protocol IDs: MK1-95, NCT00180102
3.	AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia Phase: Phase IV Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: MK1-192, NCT00180128
4.	Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC Phase: Phase IV Type: Treatment Status: Active Age: 60 and over Sponsor: Other Protocol IDs: AML_GT60_DD, NCT00180167
5.	Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Phase: Phase IV Type: Treatment Status: Active Age: 16 to 65 Sponsor: Other Protocol IDs: MCC-14178, NCT00361140
6.	Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) Phase: Phase IV Type: Treatment Status: Active Age: 0 to 75 Sponsor: Other Protocol IDs: LPA 2005, NCT00408278
7.	Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: LAP-R2007, NCT00504764
8.	Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 30052004, NCT00196768
9.	Intrabone Cord Blood Transplantation Phase: Phase IV Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: TPH/SCU-IMed 01/08, NCT00838019
10.	Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 4 to 70 Sponsor: Other Protocol IDs: RPCI-RP-9815, NCI-V99-1527, NCT00003816, RP 98-15
11.	Trial of Levofloxacin as Prophylaxis After Allogeneic Stem Cell Transplantation (SCT) Phase: Phase III, Phase II Type: Supportive care, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: Levosta-CBF-02/04, NCT00215007
12.	Stem Cell Transplantation for Hematological Malignancies Phase: Phase III, Phase II Type: Treatment Status: Active Age: 35 and under Sponsor: Other Protocol IDs: 0005M52481, MT2000-12, 2000LS040, NCT00176839
13.	Randomized Study of Decitabine in Maintenance Therapy of AML Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2006-0358, NCT00398983
14.	Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: UHW-AML16, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
15.	Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy Phase: Phase III, Phase II Type: Treatment Status: Active Age: 12 to 55 Sponsor: Pharmaceutical / Industry Protocol IDs: GC P#02.01.001, NCT00469729
16.	High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors Phase: Phase III, Phase II Type: Treatment Status: Active Age: 4 and over Sponsor: NCI Protocol IDs: RPCI-I-72806, I 72806, NCT00536601
17.	Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia Phase: Phase III, Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: IAPLSG2004, BT/PR4460/Med/14/531/2003, NCT00517712
18.	Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Phase: Phase III, Phase II Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: UMN-MT2006-13, MT2006-13, NCT00630565
19.	Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML) Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: MYFLAI07, NCT00909168
20.	Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Phase: Phase III Type: Treatment Status: Active Age: 15 to 60 Sponsor: Other Protocol IDs: EORTC-06991, NCT00004128, GIMEMA-EORTC-06991
21.	Total-Body Irradiation With Or Without Fludarabine Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Phase: Phase III Type: Treatment Status: Active Age: Under 75 Sponsor: NCI Protocol IDs: FHCRC-1813.00, 5666, NCT00075478
22.	Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E2902, E2902, NCT00093470
23.	Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide Phase: Phase III Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: AML_CR2_allo_HSCT, NCT00125606
24.	Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First Remission Phase: Phase III Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: 9005-2003, NCT00150878
25.	To Determine the Role of Adding Campath-1H or ATG Given in-Vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 230704-HMO-CTIL, NCT00226512